奥妥珠单抗：一种用于慢性淋巴细胞白血病的新型抗CD20单克隆抗体。 - Suppr

Suppr

超能文献

Obinutuzumab: A Novel Anti-CD20 Monoclonal Antibody for Chronic Lymphocytic Leukemia.

作者信息

Evans Sarah S, Clemmons Amber B

机构信息

Georgia Regents Medical Center, Augusta, Georgia, and University of Georgia College of Pharmacy, Augusta, Georgia.

出版信息

J Adv Pract Oncol. 2015 Jul-Aug;6(4):370-4. doi: 10.6004/jadpro.2015.6.4.7. Epub 2015 Jul 1.

DOI:10.6004/jadpro.2015.6.4.7

PMID:26705497

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4677809/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0961/4677809/f61d681f678c/jadp-06-370-g01.jpg

相似文献

Obinutuzumab: A Novel Anti-CD20 Monoclonal Antibody for Chronic Lymphocytic Leukemia.

J Adv Pract Oncol. 2015 Jul-Aug;6(4):370-4. doi: 10.6004/jadpro.2015.6.4.7. Epub 2015 Jul 1.

Obinutuzumab: a novel anti-CD20 monoclonal antibody for previously untreated chronic lymphocytic leukemia.

Ann Pharmacother. 2014 Oct;48(10):1356-61. doi: 10.1177/1060028014543271. Epub 2014 Jul 18.

Treating chronic lymphocytic leukemia with obinutuzumab: safety and efficacy considerations.

Expert Opin Drug Saf. 2016 Jun;15(6):865-73. doi: 10.1517/14740338.2016.1165665. Epub 2016 Apr 7.

Obinutuzumab for the treatment of chronic lymphocytic leukemia.

Drugs Today (Barc). 2014 Jun;50(6):407-19. doi: 10.1358/dot.2014.50.6.2138702.

Combination therapy with the type II anti-CD20 antibody obinutuzumab.

Expert Opin Investig Drugs. 2017 Oct;26(10):1145-1162. doi: 10.1080/13543784.2017.1373087.

Clinical application of obinutuzumab for treating chronic lymphocytic leukemia.

Drug Des Devel Ther. 2019 Aug 19;13:2899-2909. doi: 10.2147/DDDT.S212500. eCollection 2019.

Obinutuzumab for chronic lymphocytic leukemia.

Expert Rev Hematol. 2014 Oct;7(5):533-43. doi: 10.1586/17474086.2014.953478. Epub 2014 Aug 28.

Obinutuzumab, a new anti-CD20 antibody, and chlorambucil are active and effective in anti-myelin-associated glycoprotein antibody polyneuropathy.

Eur J Neurol. 2019 Feb;26(2):371-375. doi: 10.1111/ene.13838. Epub 2018 Nov 27.

Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin's lymphomas: a glycoengineered type II CD20 antibody.

Oncol Res Treat. 2015;38(4):185-92. doi: 10.1159/000381524. Epub 2015 Mar 31.

Clinical role of obinutuzumab in the treatment of naive patients with chronic lymphocytic leukemia.

Biologics. 2015 Feb 16;9:13-22. doi: 10.2147/BTT.S61600. eCollection 2015.

引用本文的文献

Characterization of anti-canine CD20 antibody 4E1-7-B_f and comparison with commercially available anti-human CD20 antibodies.

PLoS One. 2025 Jun 27;20(6):e0325526. doi: 10.1371/journal.pone.0325526. eCollection 2025.

Organising Pneumonia in a Patient Following Obinutuzumab for Follicular Lymphoma.

Respirol Case Rep. 2025 Jun 26;13(6):e70258. doi: 10.1002/rcr2.70258. eCollection 2025 Jun.

Which is the top player for the cardiovascular safety? ibrutinib vs. obinutuzumab in CLL.

Front Pharmacol. 2023 Aug 16;14:1229304. doi: 10.3389/fphar.2023.1229304. eCollection 2023.

Noncovalent antibody catenation on a target surface greatly increases the antigen-binding avidity.

Elife. 2023 May 30;12:e81646. doi: 10.7554/eLife.81646.

Comprehensive genetic and functional analyses of Fc gamma receptors influence on response to rituximab therapy for autoimmunity.

EBioMedicine. 2022 Dec;86:104343. doi: 10.1016/j.ebiom.2022.104343. Epub 2022 Nov 11.

Neutropenia in Cynomolgus Monkeys With Anti-Drug Antibodies Associated With Administration of Afucosylated Humanized Monoclonal Antibodies.

Toxicol Pathol. 2022 Dec;50(8):910-919. doi: 10.1177/01926233221131510. Epub 2022 Nov 3.

Invasive Fungal Diseases in Children with Hematological Malignancies Treated with Therapies That Target Cell Surface Antigens: Monoclonal Antibodies, Immune Checkpoint Inhibitors and CAR T-Cell Therapies.

J Fungi (Basel). 2021 Mar 5;7(3):186. doi: 10.3390/jof7030186.

Indian J Med Res. 2020 Nov;152(5):456-467. doi: 10.4103/ijmr.IJMR_43_18.

Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab.

Blood. 2019 Jan 31;133(5):494-497. doi: 10.1182/blood-2018-03-839688. Epub 2018 Nov 19.

Expansion of allogeneic NK cells with efficient antibody-dependent cell cytotoxicity against multiple tumors.

Theranostics. 2018 Jun 14;8(14):3856-3869. doi: 10.7150/thno.25149. eCollection 2018.

本文引用的文献

Hepatitis B Virus Screening for Patients With Cancer Before Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update.

J Clin Oncol. 2015 Jul 1;33(19):2212-20. doi: 10.1200/JCO.2015.61.3745. Epub 2015 May 11.

Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.

J Clin Oncol. 2014 Sep 20;32(27):3039-47. doi: 10.1200/JCO.2014.55.8262.

Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.

N Engl J Med. 2014 Mar 20;370(12):1101-10. doi: 10.1056/NEJMoa1313984. Epub 2014 Jan 8.

Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab.

Blood. 2013 Nov 14;122(20):3482-91. doi: 10.1182/blood-2013-05-504043. Epub 2013 Oct 8.

Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models.

Mol Cancer Ther. 2013 Oct;12(10):2031-42. doi: 10.1158/1535-7163.MCT-12-1182. Epub 2013 Jul 19.

Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab.

J Immunol. 2011 Mar 15;186(6):3762-9. doi: 10.4049/jimmunol.1000303. Epub 2011 Feb 4.

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

Lancet. 2010 Oct 2;376(9747):1164-74. doi: 10.1016/S0140-6736(10)61381-5.

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.

Blood. 2010 Jun 3;115(22):4393-402. doi: 10.1182/blood-2009-06-225979. Epub 2010 Mar 1.

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.

J Clin Oncol. 2010 Apr 1;28(10):1749-55. doi: 10.1200/JCO.2009.25.3187. Epub 2010 Mar 1.

Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma.

N Engl J Med. 2008 Aug 7;359(6):613-26. doi: 10.1056/NEJMra0708875.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验